-
Something wrong with this record ?
Thrombotic and Atherogenetic Predisposition in Polyglobulic Donors
N. Slaninova, I. Bryjova, Z. Lasota, R. Richterova, J. Kubicek, M. Augustynek, A. Seal, O. Krejcar, A. Proto
Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2013
PubMed Central
from 2013
Europe PubMed Central
from 2013
ProQuest Central
from 2013-01-01
Open Access Digital Library
from 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2013
- Publication type
- Journal Article MeSH
This work analyses the results of research regarding the predisposition of genetic hematological risks associated with secondary polyglobulia. The subjects of the study were selected based on shared laboratory markers and basic clinical symptoms. JAK2 (Janus Kinase 2) mutation negativity represented the common genetic marker of the subjects in the sample of interest. A negative JAK2 mutation hypothetically excluded the presence of an autonomous myeloproliferative disease at the time of detection. The parameters studied in this work focused mainly on thrombotic, immunological, metabolic, and cardiovascular risks. The final goal of the work was to discover the most significant key markers for the diagnosis of high-risk patients and to exclude the less important or only complementary markers, which often represent a superfluous economic burden for healthcare institutions. These research results are applicable as a clinical guideline for the effective diagnosis of selected parameters that demonstrated high sensitivity and specificity. According to the results obtained in the present research, groups with a high incidence of mutations were evaluated as being at higher risk for polycythemia vera disease. It was not possible to clearly determine which of the patients examined had a higher risk of developing the disease as different combinations of mutations could manifest different symptoms of the disease. In general, the entire study group was at risk for manifestations of polycythemia vera disease without a clear diagnosis. The group with less than 20% incidence appeared to be clinically insignificant for polycythemia vera testing and thus there is a potential for saving money in mutation testing. On the other hand, the JAK V617F (somatic mutation of JAK2) parameter from this group should be investigated as it is a clear exclusion or confirmation of polycythemia vera as the primary disease.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017382
- 003
- CZ-PrNML
- 005
- 20220720100216.0
- 007
- ta
- 008
- 220718s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/biomedicines10040888 $2 doi
- 035 __
- $a (PubMed)35453637
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Slaninova, Nikola $u Department of Cybernetics and Biomedical Engineering, VŠB-Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic
- 245 10
- $a Thrombotic and Atherogenetic Predisposition in Polyglobulic Donors / $c N. Slaninova, I. Bryjova, Z. Lasota, R. Richterova, J. Kubicek, M. Augustynek, A. Seal, O. Krejcar, A. Proto
- 520 9_
- $a This work analyses the results of research regarding the predisposition of genetic hematological risks associated with secondary polyglobulia. The subjects of the study were selected based on shared laboratory markers and basic clinical symptoms. JAK2 (Janus Kinase 2) mutation negativity represented the common genetic marker of the subjects in the sample of interest. A negative JAK2 mutation hypothetically excluded the presence of an autonomous myeloproliferative disease at the time of detection. The parameters studied in this work focused mainly on thrombotic, immunological, metabolic, and cardiovascular risks. The final goal of the work was to discover the most significant key markers for the diagnosis of high-risk patients and to exclude the less important or only complementary markers, which often represent a superfluous economic burden for healthcare institutions. These research results are applicable as a clinical guideline for the effective diagnosis of selected parameters that demonstrated high sensitivity and specificity. According to the results obtained in the present research, groups with a high incidence of mutations were evaluated as being at higher risk for polycythemia vera disease. It was not possible to clearly determine which of the patients examined had a higher risk of developing the disease as different combinations of mutations could manifest different symptoms of the disease. In general, the entire study group was at risk for manifestations of polycythemia vera disease without a clear diagnosis. The group with less than 20% incidence appeared to be clinically insignificant for polycythemia vera testing and thus there is a potential for saving money in mutation testing. On the other hand, the JAK V617F (somatic mutation of JAK2) parameter from this group should be investigated as it is a clear exclusion or confirmation of polycythemia vera as the primary disease.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bryjova, Iveta $u Department of Cybernetics and Biomedical Engineering, VŠB-Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic
- 700 1_
- $a Lasota, Zenon $u Blood Donor Center, tr. T. G. Masaryka 495, 738 01 Frydek-Mistek, Czech Republic
- 700 1_
- $a Richterova, Radmila $u Blood Donor Center, tr. T. G. Masaryka 495, 738 01 Frydek-Mistek, Czech Republic
- 700 1_
- $a Kubicek, Jan $u Department of Cybernetics and Biomedical Engineering, VŠB-Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic
- 700 1_
- $a Augustynek, Martin $u Department of Cybernetics and Biomedical Engineering, VŠB-Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic $1 https://orcid.org/0000000201657317 $7 ola2011639627
- 700 1_
- $a Seal, Ayan $u Department of Computer Science & Engineering, PDPM Indian Institute of Information Technology, Design and Manufacturing, Jabalpur 482005, India $u Center for Basic and Applied Research, Faculty of Informatics and Management, University of Hradec Kralove, Hradecka 1249, 500 03 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000299392926
- 700 1_
- $a Krejcar, Ondrej $u Center for Basic and Applied Research, Faculty of Informatics and Management, University of Hradec Kralove, Hradecka 1249, 500 03 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000259922574
- 700 1_
- $a Proto, Antonino $u Department of Cybernetics and Biomedical Engineering, VŠB-Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic $1 https://orcid.org/0000000319648184
- 773 0_
- $w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 10, č. 4 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35453637 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220718 $b ABA008
- 991 __
- $a 20220720100211 $b ABA008
- 999 __
- $a ind $b bmc $g 1816566 $s 1168624
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 10 $c 4 $e 20220412 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
- LZP __
- $a Pubmed-20220718